1. Generics Bulletin
  2. >>Archive

Mylan has rival to Exelon in US

Mylan has launched in the US a generic version of Mylan’s Exelon (rivastigmine) 4.6mg/24-hour, 9.5mg/24-hour and 13.3mg/24- hour transdermal patches, after receiving approval from the US Food and Drug Administration (FDA).

Mylan has launched in the US a generic version of Mylan’s Exelon (rivastigmine) 4.6mg/24-hour, 9.5mg/24-hour and 13.3mg/24- hour transdermal patches, after receiving approval from the US Food and Drug Administration (FDA).

Citing Iqvia data, Mylan observed that the rivastigmine transdermal system in the three doses had US sales of approximately US$248...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin

US Court Agrees To Throw Out Viatris Wegovy Infringement Case

 
• By Dean Rudge

Viatris’ Mylan has won a key patent case against Novo Nordisk over generic Wegovy, with a US federal district judge ruling Mylan’s label did not encourage use that infringed Novo’s method-of-treatment patent.

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By Dave Wallace

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

‘By Most Measures A Failure’: Ten Years On From Teva-Actavis

 
• By Dean Rudge

A decade after Teva’s $40.5bn acquisition of Actavis Generics, the deal remains a defining moment for the company. This retrospective explores Teva’s hopes, consequences, leadership shifts, and the firm’s new growth strategy under CEO Richard Francis.